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ABSTRACT: 33 
 34 
The synthesis of 14 new optically pure C1-symmetric phosphane–phosphinite (1–4), phosphane–35 
phosphite (5–9) and phosphane–phosphorodiamidite (10–14) ligands is reported. The ligands were 36 
prepared through the condensation of (2-hydroxyphenyl)phenylphosphanes PPh(2-PhOH)R (R = Me, 37 
tBu and Ph) with chlorodiisopropylphosphane (1 and 2), chlorodiphenylphosphine (3 and 4), the 38 
chlorodioxaphosphepine derived from both enantiomers of 1,1′-bi-2-naphthol (5–9) and the 39 
chlorodiazaphosphepine derived from both enantiomers of N,N′-dimethyl-1,1′-binaphthyl-2,2′-diamine 40 
(10–14) in the presence of a base. With these ligands, cationic Pd complexes of the type [Pd(η3-41 
C4H7)(PP′)]PF6 (Pd1–Pd14) were obtained and characterised; the crystal structures of Pd1, Pd2 and 42 
Pd13 were obtained. In solution, the complexes are present as mixtures of two diastereomers because of 43 
the lack of symmetry of the ligand and the presence of the methallyl group. The Pd complexes catalyse 44 
the allylic alkylation with dimethyl malonate and the amination with benzylamine of the model substrate 45 
rac-3-acetoxy-1,3-diphenyl-1-propene (I). For the alkylation, full conversions and good 46 
enantioselectivities (up to 96 % ee with Pd14) were observed. 47 
 48 
 49 
50 
INTRODUCTION 51 
 52 
Chiral phosphorus-based ligands have dominated asymmetric transition-metal homogeneous catalysis 53 
for more than 50 years.[1] Many of the most successful ligands are C2-symmetric diphosphanes,[2] 54 
which were initially thought to be superior ligands to monophosphanes or C1-symmetric ligands as the 55 
reduced number of intermediates and transition states in each step of a catalytic cycle would lead to 56 
higher enantioselectivities and simpler analysis of the results. 57 
However, a much more complicated picture has now emerged. Although certain structural motifs lead to 58 
especially active and enantioselective ligands,[3] there will clearly never be a “universal ligand” suitable 59 
for all reactions and substrates. Therefore, all possible sources of structural diversity have been explored 60 
actively for the last two decades, and old dogmas and preconceptions have been revised or 61 
abandoned.[3,4] Nowadays, very active and enantioselective catalysts can contain ligands that are not 62 
phosphanes but possess one or more P–heteroatom bonds,[5] including many monophosphorus 63 
ligands.[6] It is also widely accepted that the previously ubiquitous C2-symmetric diphosphorus ligands 64 
(PP) are not better per se than their C1-symmetric counterparts (PP′).[5a,5c,7] Finally, a strong 65 
resurgence of P-stereogenic ligands has also occurred.[4b,8] The extraordinary activity in the area of 66 
ligand design is understandable for the ever-increasing demand of optically pure compounds in 67 
pharmaceutical, agrochemical and other fields and is evident from the number of recent reviews[5b,7,9] 68 
and monographs[ 4] about the synthesis of chiral phosphorus-based ligands. 69 
Only a few C1-symmetric diphosphorus ligands containing both a P-stereogenic phosphane and another 70 
phosphorus donor unit with a P–heteroatom bond have been reported.[10] 71 
We have been working on the synthesis and catalytic applications of many chiral mono- and bidentate 72 
aminophosphane,[11] phosphinite,[12] phosphite[13] and phosphorodiamidite[14] ligands in several 73 
catalytic reactions. We have also been working on the synthesis and catalytic applications of P-74 
stereogenic ligands.[12a,12b,15] 75 
Therefore, it was deemed interesting to devote some effort to merge both areas of our previous research 76 
and prepare a few PP′ (P = P-stereogenic phosphane; P′ = phosphinite, phosphite or phosphorodiamidite) 77 
ligands and evaluate their catalytic potential. In this paper, we describe the synthesis of these ligands 78 
and their derived Pd complexes as well as their application as catalyst precursors in allylic substitution 79 
reactions. 80 
 81 
.82 
RESULTS AND DISCUSSION 83 
 84 
Ligand Synthesis 85 
Upon analysing the possible routes to obtain modular P-stereogenic PP′ ligands with an appropriate 86 
bridge to form bidentate ligands, it was concluded that a relatively easy way would be the condensation 87 
reaction between an electrophilic chlorophosphorus precursor and a configurationally stable P-88 
stereogenic 2-hydroxyphenylphosphane in the presence of base. Such reactions would yield PP′ ligands 89 
with rigid 2-oxyphenyl bridges between the two phosphorus atoms (Scheme 1). 90 
An early paper of Pringle and Baker[16] described the preparation of one such ligand (see later), 91 
whereas Pizzano and coworkers have used this scaffold to prepare a series of phosphane–phosphite 92 
ligands and used them in Rh-[10f,10g,10l,17] and Ir-catalysed[10i,18] hydrogenations and in Rh-93 
catalysed hydroformylation;[10l] however, only a few of their ligands possess a P-stereogenic 94 
phosphane moiety. 95 
The required P-stereogenic 2-hydroxyphenylphosphanes are accessible as optically pure compounds by 96 
the well-known Jugé–Stephan method[19] starting from oxaphospholidine–borane A. Therefore, we 97 
started by reproducing the work of Stephan and co-workers,[20] who described the preparation of 2-98 
hydroxyphenylphosphinite–borane B, and we obtained 2-hydroxyphenylphosphane C·BH3 by treatment 99 
with excess methyllithium (Scheme 2). 100 
A solution of B was also treated with excess tert-butyllithium to afford the corresponding 2-101 
hydroxyphenylphosphane–borane C′·BH3. It has to be noted that it is very difficult[21] to introduce the 102 
tert-butyl group to a phosphane through the Jugé–Stephan method. However, in this case, it seems that 103 
the presence of an oxygen-containing group at the ortho position relative to the P atom facilitates the 104 
organolithium attack.[21a,21c] Phosphane–boranes C·BH3 and C′·BH3 were deboronated by treatment 105 
with tetrafluoroboric acid to yield the free phosphinophenols C and C′ as air-sensitive semisolids. The 106 
absolute configurations of the phosphorus atoms, expected to be S, could be verified by the crystal 107 
structures of the Pd complexes of the ligands (described below). The preparation of the achiral 108 
phosphinophenol C′′ was not required because it is commercially available. To complete the synthesis of 109 
the ligands, phosphinophenols C–C′′ were treated with the appropriate chlorophosphorus precursors 110 
(either commercially available or described previously)[14] in the presence of amines as detailed in the 111 
Experimental Section. After the removal of the ammonium salts by filtration and exhaustive drying 112 
under vacuum, the desired PP′ ligands were finally obtained as pasty solids. The ligands prepared in the 113 
present work are shown in Figure 1. 114 
To the best of our knowledge, all of the prepared ligands are new except ligand 9, which was described 115 
by Baker and Pringle[16] and used by Pizzano and co-workers in Rh-catalysed hydrogenation.[17b] The 116 
ligands were characterised by 1H and 31P{1H} NMR spectroscopy, which supported the structures 117 
depicted in Figure 1. In general, two doublets (4JP,P = 0–41 Hz) were observed in the 31P{1H} NMR 118 
spectra, and the coupling constants are strongly dependent on the ligand. The coupling constants for the 119 
phosphane–phosphinite ligands 1–4 are rather small (0–4 Hz), but those for phosphane–phosphite 120 
ligands 5–9 are much larger (15–42 Hz), whereas those for the phosphane–phosphorodiamidite ligands 121 
10–14 have intermediate values (7–16 Hz). As expected,[14a] small differences in the 31P{1H} NMR 122 
chemical shifts for each of the members in the diastereomeric pairs 5/7, 6/8, 10/12 and 11/13 could be 123 
spotted. In the 1H NMR spectra of phosphane–phosphorodiamidite ligands 10–14, two doublets 124 
appeared for the two inequivalent N–Me groups coupled to the phosphorus atom, as previously reported 125 
for related compounds.[14a] A more thorough characterisation was not possible owing to the rapid 126 
degradation of the ligands by oxidation, hydrolysis, or both if they were not kept under a protective 127 
nitrogen atmosphere. Therefore, the ligands were not stored but used immediately for complexation to 128 
Pd as described in the following section. 129 
 130 
Preparation of Pd Complexes 131 
The reaction of the Pd dimer D with 2 equiv. of ligand in dichloromethane in the presence of excess 132 
ammonium hexafluorophosphate[ 12b,12c] yielded the expected cationic complexes of the type [Pd(η3-133 
C4H7)(PP′)]PF6 (Pd1–Pd14) as white or pale yellow solids after workup (Scheme 3). 134 
The characterisation of solutions of the complexes by multinuclear (31P{1H}, 1H, and in some cases 135 
13C{1H}) NMR spectroscopy revealed duplicate peaks indicative of the existence of two 136 
diastereoisomeric species owing to the lack of C2 symmetry of the bidentate ligand and the presence of 137 
the η3-methallyl moiety, as previously observed for neutral complexes of the type [Pd(η3-C4H7)Cl(P)] 138 
(P = chiral monophosphorus ligand).[12a,12c,14a,14c,22] The integration of the 31P{1H} and 1H NMR 139 
spectra allowed the estimation of the diastereomeric ratio for each complex. There does not seem to be a 140 
simple correlation between the structures of the complexes and their diastereomeric ratios, which varied 141 
from 1:1 (Pd2, Pd4, Pd7, Pd12 and Pd14) to a maximum of 1:2.7 for Pd5. In the 31P{1H} NMR spectra, 142 
two sharp pairs of doublets, one for each diastereomer, are indicative of AX spin systems. The 2JP,P′ 143 
values are in the range previously reported for related compounds[14d,23] and follow the same trends as 144 
the 4JP,P′ values for the free ligands. The 31P coordination chemical shifts (CCS, defined as δcomplex–145 
δfree ligand) of the phosphane fragments are approximately +30 ppm for the complexes, as expected. In 146 
contrast, the other phosphorus moiety shows a larger sensitivity to coordination The CCS values are 147 
approximately +40 ppm for phosphinite complexes Pd1–Pd4, +2 ppm for phosphite complexes Pd5–Pd9 148 
and –15 ppm for phosphorodiamidite complexes Pd10–Pd14. The shielding of the P atom of the 149 
phosphorodiamidite upon coordination is probably due to the low σ donation of this part of the ligand 150 
and has been reported for the complexation of other chiral phosphorodiamidite ligands.[14,24] 151 
In 1H NMR spectra, two sets of peaks associated with the aliphatic protons of each ligand are observed 152 
(see Experimental Section and Table S1 of the Supporting Information for details). For Pd10–Pd14 153 
bearing the phosphane–phosphorodiamidite ligands, two pairs of doublets, one for each isomer, account 154 
for the methyl groups of the diazaphosphepine part of the ligand. Interestingly, the 3JH,P coupling 155 
constants are clearly different for the two methyl groups of each isomer (ca. 10 and 15 Hz), and the 156 
same can be observed in the 13C{1H} NMR spectra, in which 2JC,P ≈ 12 and 30 Hz. This suggests that 157 
the amino groups have a different orientation in solution with respect to the P–Pd bond, as observed in 158 
the solid state (vide infra) and for previously reported related compounds.[14d,24,25] 159 
For the methallyl group, the 1H NMR spectra (Table S1) confirm the presence of two diastereomers. 160 
Hence, two singlets at δ = 1.3–2.0 ppm account for the methyl group, whereas two sets of four peak in 161 
the range δ = 2.3–4.8 ppm can be assigned to the four protons of the methallyl group. As 162 
expected,[14a,14d,22,23] the anti protons usually appear at higher fields (δ = 2.3–3.8 ppm) as doublets 163 
with coupling constants of ca. 10 Hz owing to the coupling with the phosphorus atom at the relative 164 
trans position. In a few cases, they appear as doublets of doublets, also coupled to the phosphorus atom 165 
at the cis position. At lower fields (δ = 3.6–4.8 ppm), two sets of syn protons appear as broad singlets, 166 
doublets, doublets of doublets or multiplets. For these protons, the coupling constants are smaller, as 167 
commonly found for comparable systems.[14a,14d,22,23] In the 13C{1H} NMR spectra (Table S1), the 168 
methylene termini of the methallyl groups appeared as doublets or doublets of doublets owing to the 169 
coupling with one or two phosphorus atoms, respectively. The difference in the chemical shifts, which 170 
has been used to evaluate the asymmetry of the allyl bonding,[26] ranged from 2.5 ppm for one of the 171 
isomers of Pd3 to 13.6 ppm for one of the isomers of Pd2. 172 
For Pd1, Pd2 and Pd13, single crystals suitable for X-ray diffraction studies were obtained by layering 173 
hexane on solutions of the complexes in dichloromethane. For all of these complexes, the structures are 174 
composed of discrete molecules of the cationic complex, hexafluorophosphate anions and 175 
dichloromethane molecules as well as adventitious water molecules for Pd13 separated by van der 176 
Waals distances. It is interesting to note that only one diastereomer was found in all of the crystals 177 
analysed. Representations of the molecular structures of Pd1 and Pd2 and a selection of bond lengths 178 
and angles are given in Figure 2. 179 
For both structures, the palladium atom sits in a distorted square-planar geometry, coordinated to the 180 
two phosphorus atoms and to the terminal C atoms of the methallyl moiety. The metric parameters are in 181 
the ranges expected for cationic allylpalladium complexes.[12b,14d,22] For both structures, the Pd–182 
Callyl distance trans to the phosphinite moiety is longer than the Pd–Callyl distance trans to the 183 
phosphane moiety, especially for Pd2. The same trend has been found for comparable complexes.[27] 184 
The X-ray structure of the phosphane–phosphorodiamidite complex Pd13 is depicted in Figure 3. 185 
The complex has a distorted square-planar geometry around the palladium atom, and the coordination 186 
positions are occupied by the two phosphorus atoms of the ligand and the two terminal atoms of the 187 
methallyl fragment. The distances and angles are similar to those for comparable complexes.[14d] The 188 
Pd–Callyl distance trans to the phosphorodiamidite fragment is longer than the Pd–Callyl distance trans 189 
to the phosphane moiety, as observed for complexes containing comparable phosphane–190 
phosphoramidite ligands.[27] The two P–N bond lengths are different and in the range found for similar 191 
compounds.[14a,14c,14d] The values suggest a partial double-bond character, as found in related 192 
complexes.[14d] The sums of the bond angles around both nitrogen atoms are close to 360°; therefore, 193 
the coordination is close to planarity, as occurs for related complexes.[14d,25] The torsion angle of the 194 
binaphthyl group is 59.14°. 195 
It is interesting to note that the longest Pd–Callyl distance in all the three crystal structures is always in 196 
the cis position with respect to the P-stereogenic phosphane group.  197 
Pd-Catalysed Allylic Substitution The performance of the ligands 1–14 was tested in Pd-catalysed 198 
asymmetric allylic substitution reactions with the model substrate rac-3-acetoxy-1,3-diphenyl-1-propene 199 
(I) and the cationic palladium complexes Pd1–Pd14 (Scheme 4). 200 
The studied allylic substitutions involved alkylation with the C-nucleophile derived from dimethyl 201 
malonate (DMM) in the presence of N,O-bis(trimethylsilyl)acetamide (BSA) and potassium acetate and 202 
amination with benzylamine. The obtained results are given in Table 1. 203 
All of the complexes were active in the allylic alkylations and provided complete conversions in 24 h 204 
with 1 % of complex. A wide range of ee values (5–96 %) was obtained, in line with the results for other 205 
C1-symmetric diphosphorus ligands.[10d,27,28] The complexes with phosphane–phosphinite ligands, 206 
containing only the phosphorus atom as a stereogenic element (Table 1, Entries 1–4), led to the lowest 207 
enantioselectivities, and Pd4 achieved a moderate value of 45 % ee (Table 1, Entry 4). The results with 208 
the other complexes with two stereogenic elements (Table 1, Entries 5–14) allow the discussion of the 209 
match–mismatch effects between them. A general trend is that the enantioselectivities are considerably 210 
higher than those for complexes containing phosphane–phosphinite ligands, and this highlights the 211 
efficiency of the 1,1′-binaphthyl unit as a chiral inductor. Indeed, most of the ligands give very 212 
enantioselective systems that afford similar or better results than those with other phosphane–213 
phosphite[10d,28a] or phosphane–phosphoramidite ligands[27] except Pd7, Pd11 and Pd13 (Table 1, 214 
Entries 7, 11 and 13). There is a match–mismatch effect between the absolute configurations of the 1,1′-215 
bi-2-naphthyl fragment of the phosphite or phosphorodiamidite moiety and the stereogenic phosphorus 216 
atom. Clearly, the matched combination corresponds to the (Ra,SP) ligands (cf. Table 1, Entries 5 vs. 7, 217 
6 vs. 8, 10 vs. 12 and 11 vs. 13). The absolute configurations of the alkylation product are controlled by 218 
the absolute configuration of the phosphite or phosphorodiamidite part of the ligand; therefore, (Ra) 219 
ligands preferentially produce the (R)-alkylation product (Table 1, Entries 5, 6, 10 and 11), whereas (Sa) 220 
ligands give the (S)-alkylation product (Table 1, Entries 7–9 and 12–14). The same fact was observed by 221 
van Leeuwen and co-workers[10d] for related phosphane–phosphite ligands with a more flexible bridge. 222 
The only relevant difference between the Pstereogenic phosphane–phosphite (Table 1, Entries 5–9) and 223 
phosphane–phosphorodiamidite (Table 1, Entries 10–13) complexes is that the complexes bearing the 224 
tBu-containing phosphanes are more selective than the Me counterparts for the former (cf. Table 1, 225 
Entries 5 vs. 6 and 7 vs. 8), whereas the trend is the opposite for the latter (cf. Table 1, Entries 10 vs. 11 226 
and 12 vs. 13). The best results were obtained with Pd6, Pd9 and Pd14 (Table 1, Entries 6, 9 and 14), the 227 
latter two of which contain an achiral phosphane moiety. 228 
Palladium complexes Pd1–Pd14 were also tested in the allylic amination of I with excess benzylamine. 229 
The systems are much slower in the allylic amination than in the alkylation, as reported for related 230 
phosphite–phosphoramidite ligands,[29] and the complexes with phosphane–phosphite ligands are 231 
totally inactive (Table 1, Entries 5–9). The other complexes led to low or moderate conversions at best. 232 
The complexes with phosphane–phosphinite ligands gave very poor enantioselectivities (Table 1, 233 
Entries 1–4), whereas those with phosphane–phosphorodiamidite ligands (Table 1, Entries 10–14) were 234 
slightly better. Complex Pd14, containing an achiral phosphane moiety, is clearly the best of the series 235 
in terms of activity and enantioselectivity. In this case, (Ra) ligands gave preferentially the (S) amination 236 
product, which is the same sense of induction as in the alkylation reaction, as the amination product has 237 
the opposite absolute configuration to the alkylation product owing to a change of priority of the groups 238 
in the Cahn–Ingold–Prelog (CIP) rules. 239 
To help to rationalise the absolute configurations of the substitution products of I, complex Pd6′, bearing 240 
ligand 6 and the 1,3-diphenylallyl moiety, was prepared and characterised (Scheme 5). 241 
This complex is one of the intermediates in the substitution of I with ligand 6. In solution, it is present as 242 
a mixture of two diastereomers in a 1:3.5 ratio, whereas this ratio was 1:2.3 for Pd6. Unfortunately, we 243 
were unable to obtain any crystals of Pd6′ suitable for X-ray diffraction. From the crystal structure data 244 
of Pd1, Pd2 and Pd13, it seems that the phosphane (P) part exerts a lower trans influence than the other 245 
phosphorus moiety (P′). In principle, this means that the most electrophilic carbon atom of the allyl 246 
group and the one that will be preferentially attacked by the nucleophile will be the one at the cis 247 
position relative to the phosphane part. We assumed that the same trends would apply to the 1,3-248 
diphenylallyl complexes and performed PM3-level calculations of the energies of the diastereomers of 249 
Pd6′, Pd8′, Pd9′ and Pd14′ (see Supporting Information). The absolute configuration of the substitution 250 
product resulting from the attack of the nucleophile at the allylic carbon atom cis to the phosphane 251 
moiety in the most stable isomer is coherent with the absolute configuration of the major enantiomer 252 
obtained experimentally. 253 
We also studied the alkylations of cyclohexen-3-yl acetate (II) and cinnamyl acetate (III) with DMM 254 
(Scheme 6). 255 
The more enantioselective catalysts Pd6 and Pd14 were chosen to study their potential in the alkylation 256 
of substrate II. As very low conversions and enantioselectivities were found within 24 h of reaction 257 
time, no more catalytic runs with this substrate were carried out. Finally, some of the complexes were 258 
tested in the alkylation of III. The complexes led to full conversions at 1 h reaction times, but, as 259 
expected,[12b] the achiral linear alkylation product (l) was favoured over the branched isomer (b). The 260 
full results can be found in Table S2 of the Supporting Information. 261 
262 
CONCLUSIONS 263 
 264 
The preparation of 14 new, chiral phosphane–phosphinite, phosphane–phosphite and phosphane–265 
phosphorodiamidite ligands has been reported. Most of them bear a stereogenic phosphorus atom and 266 
have been conveniently prepared by a condensation reaction between a phosphinophenol and a 267 
chlorophosphorus precursor. Many of the ligands include phosphite and phosphorodiamidite parts with a 268 
chiral 1,1′-binaphthyl moiety. The ligands have been designed to have one or two stereogenic elements 269 
to increase their modularity and to study the influence of the different combinations on the catalysis. 270 
The cationic Pd complexes of the ligands with η3-methallyl coligands have been prepared and 271 
characterised in solution by NMR spectroscopy and also by X-ray crystallography for Pd1, Pd2 and 272 
Pd13. They are good catalytic precursors for allylic substitutions (alkylation with DMM and amination 273 
with benzylamine) with substrates I, II and III. In the alkylation of I, all of the complexes gave full 274 
conversion to the alkylation product after 24 h, and very high enantioselectivities (up to 95 % ee) were 275 
obtained with Pd6 and Pd14. The stereochemical course of the reaction is coherent with the nucleophilic 276 
attack at the allylic carbon atom in cis position relative to the phosphane. Some match–mismatch effects 277 
have been identified, and it is the absolute configuration of the 1,1′-binaphthyl-based phosphite or 278 
phosphorodiamidite part of the ligand that dictates the absolute configuration of the alkylation product, 279 
but the phosphane part also has some influence on the level of enantioselection. 280 
Given the results presented here and the high modularity of the ligands, we are currently preparing new 281 
ligands of the same type and using them and the reported ones in new catalytic reactions. The results of 282 
these studies will be reported in due course. 283 
 284 
 285 
286 
EXPERIMENTAL SECTION 287 
 288 
General Data: All compounds were prepared under a purified nitrogen atmosphere by standard Schlenk 289 
and vacuum-line techniques. The solvents were obtained from a solvent-purification system or purified 290 
by standard procedures[30] and kept under nitrogen. 1H, 13C{1H}, 31P{1H} and HSQC 1H–13C NMR 291 
spectra were recorded with 300 and 400 MHz spectrometers with CDCl3 as the solvent. The protons of 292 
the BH3 moieties of the phosphane–boranes appeared in the aliphatic region of the spectra as very broad 293 
bands and have not been assigned. For the Pd complexes, ma and mi refer to the major and minor 294 
diastereomers of the complexes, respectively. The IR spectra were recorded with samples in KBr, and 295 
the main absorption bands are expressed in cm–1. High-resolution mass spectrometry analyses were 296 
performed with electrospray ionisation. The optical rotations were measured at room temperature with a 297 
sodium lamp at the sodium D-line wavelength (589.592 nm). In all cases, the solvent was CH2Cl2, and 298 
the concentration was 1 g/100 mL. The allylic substitution reactions of I were analysed with an HPLC 299 
instrument equipped with a multidiode array detector and fitted with an OD-H chiral column. The eluent 300 
was a 95:5 n-hexane/iPrOH mixture. The allylic alkylations of II and III were analysed by GC with a 301 
chromatograph equipped with a capillary column with He as the carrier gas and a flame-ionisation 302 
detector (FID). Phosphinite–borane B [prepared from 1,[19] which was prepared from (1R,2S)-(–)-303 
ephedrine],[20] phosphane–borane C·BH3,[20] the chlorodiazaphosphosphepine derived from N,N′-304 
dimethyl-1,1′-binaphthyl-2,2′-diamine,[14] Pd dimers D[31] and D′[32] and substrates I[33] and III[34] 305 
were prepared by literature procedures, whereas other reagents were used as received from commercial 306 
suppliers. CCDC 1461787 (for Pd1), 1461788 (for Pd2) and 1461789 (for Pd3) contain the 307 
supplementary crystallographic data for this paper. These data can be obtained free of charge from The 308 
Cambridge Crystallographic Data Centre. 309 
 310 
(S)-(tert-Butyl)(2-hydroxyphenyl)phenylphosphane–Borane (C′· BH3): Phosphinite–borane B (528 311 
mg, 2.1 mmol) was dissolved in diethyl ether (30 mL), and the mixture was cooled to –30 °C. A 1.6 M 312 
solution of tBuLi (3.1 mL, 5.0 mmol) was added by syringe, and the mixture was stirred for 1 h and left 313 
to warm to room temperature. Water (20 mL) was added carefully, the biphasic mixture was extracted 314 
with diethyl ether (3 × 10 mL), and the combined organic phases were washed with water (20 mL). The 315 
final organic phase was dried with anhydrous sodium sulfate and filtered, and the solvent was removed 316 
under vacuum to furnish the title product as an oil, yield 553 mg (97 %). 1H NMR (400 MHz): δ = 8.06 317 
(s, br, 1 H), 7.79–7.74 (m, 2 H), 7.51–7.37 (m, 4 H), 7.24–7.19 (m, 1 H), 6.98 (ddd, J = 8.4, 5.2, 1.2 Hz, 318 
1 H), 6.88 (tm, J = 6.8 Hz, 1 H), 1.38 (d, 3JH,P = 14.8 Hz, 9 H) ppm. 13C{1H} NMR (101 MHz): δ = 319 
161.8–109.9 (C, CH, Ar), 32.2 (d, 1JC,P = 32.7 Hz, C), 26.7 (d, 2JC,P = 3.0 Hz, 3 × CH3) ppm. 320 
31P{1H} NMR (162 MHz): δ = +26.6 (d, br, 1JB,P = 71.0 Hz) ppm. HRMS: calcd. for C16H21BOP [M 321 
– H]+ 271.1417; found 271.1406. [α]D = +140.8 (CH2Cl2, c = 1). HPLC analysis with a chiral column 322 
indicated that the compound was essentially enantiopure (see HPLC trace in the Supporting 323 
Information). 324 
 325 
(S)-(2-Hydroxyphenyl)methylphenylphosphane (C): Phosphane–borane C·BH3 (310 mg, 1.2 mmol) 326 
was dissolved in dichloromethane, and the solution was cooled to 0 °C. HBF4·Et2O (0.87 mL, 6.3 327 
mmol) was added rapidly by syringe, the mixture was vigorously stirred for 1 h and deoxygenated 328 
thoroughly, and a saturated aqueous NaHCO3 solution (10 mL) was added carefully. The organic layer 329 
was transferred to another flask, washed with thoroughly with deoxygenated water, dried with 330 
anhydrous sodium sulfate, filtered and brought to dryness under vacuum. The title product was obtained 331 
as an air-sensitive colourless oil, yield 200 mg (73 %). The characterisation data of this compound 332 
agreed with the data reported previously.[10f,35] 333 
 334 
(S)-(tert-Butyl)(2-hydroxyphenyl)phenylphosphane (C′): The procedure was the same as that used to 335 
obtain C. From phosphane–borane C′·BH3 (1000 mg, 3.7 mmol) and HBF4·Et2O (2.3 mL, 16.7 mmol), 336 
the title product was obtained as a colourless oil, yield 860 mg (90 %). The characterisation data of this 337 
compound agreed with the values reported previously.[36] 1H NMR (400 MHz): δ = 7.74–7.70 (m, 2 338 
H), 7.67–7.64 (m, 1 H), 7.30–7.28 (m, 2 H), 7.25–7.23 (m, 3 H), 6.96–6.92 (m, 1 H), 1.28 (d, 3JH,P = 339 
13.6 Hz, 9 H) ppm. 13C{1H} NMR (101 MHz): δ = 161.0–115.3 (C, CH, Ar), 31.4 (d, 1JC,P = 7.8 Hz, 340 
C), 28.5 (d, 2JC,P = 13.8 Hz, CH3) ppm. 31P{1H} NMR (162 MHz): δ = –19.0 (s) ppm. 341 
 342 
Compound 1: Hydroxyphosphane C (345 mg, 1.5 mmol) was dissolved in toluene (20 mL), and 343 
triethylamine (0.3 mL, 2.2 mmol) was added rapidly by syringe. To this mixture, a solution of 344 
chlorodiisopropylphosphane (0.24 mL, 1.5 mmol) in toluene (15 mL) was added dropwise over 15 min, 345 
and the suspension was stirred for 1 h. The ammonium salts were removed by filtration, and the filtrate 346 
was brought to dryness to afford the title product as a pasty, white solid, yield 445 mg (90 %). 1H NMR 347 
(400 MHz): δ = 7.43–7.35 (m, 3 H), 7.30–7.27 (m, 3 H), 7.26–7.23 (m, 1 H), 7.10 (ddd, J = 7.6, 4.4, 1.6 348 
Hz, 1 H), 6.95 (tm, J = 7.6 Hz, 1 H), 1.90 (m, 1 H), 1.68 (m, 1 H), 1.54 (d, 3JH,P = 4.4 Hz, 3 H), 1.17 349 
(dd, 3JH,P, 3JH,H = 10.8, 6.8 Hz, 3 H), 1.07 (dd, 3JH,P, 3JH,H = 16.0, 7.6 Hz, 3 H), 0.94 (dd, 3JH,P, 350 
3JH,H = 16.0, 7.2 Hz, 3 H), 0.82 (dd, 3JH,P, 3JH,H = 11.2, 6.8 Hz, 3 H) ppm. 31P{1H} NMR (162 351 
MHz): δ = +145.1 (s), –37.5 (s) ppm.  352 
 353 
Compound 2: The procedure was the same as that used to obtain 1. From hydroxyphosphane C′ (284 354 
mg, 1.1 mmol), the title product was obtained as a white, pasty solid, yield 387 mg (94 %). 1H NMR 355 
(400 MHz): δ = 7.52 (dt, J = 7.6, 2.0 Hz, 1 H), 7.41–7.35 (m, 3 H), 7.27–7.22 (m, 4 H), 6.94 (td, J = 7.6, 356 
1.2 Hz, 1 H), 2.01 (m, 1 H), 1.88 (m, 1 H), 1.23 (d, 3JH,P = 12.4 Hz, 9 H), 1.18 (dd, 3JH,P, 3JH,H = 357 
11.2, 7.2 Hz, 3 H), 1.05 (dd, 3JH,P, 3JH,H = 15.6, 7.2 Hz, 3 H), 0.86 (dd, 3JH,P, 3JH,H = 15.6, 7.2 Hz, 358 
3 H), 0.75 (dd, 3JH,P, 3JH,H = 11.6, 7.2 Hz, 3 H) ppm. 31P{1H} NMR (162 MHz): δ = +145.9 (d, 359 
4JP,P = 1.1 Hz), +2.0 (d, 4JP,P = 1.1 Hz) ppm. 360 
 361 
Compound 3: The procedure was analogous to that used to obtain 1. From hydroxyphosphane C (130 362 
mg, 0.60 mmol) and chlorodiphenylphosphine (0.11 mL, 0.6 mmol), the title product was obtained as a 363 
white, pasty solid, yield 201 mg (84 %). 1H NMR (400 MHz): δ = 7.80–7.73 (m, 2 H), 7.72–7.68 (m, 1 364 
H), 7.61–7.48 (m, 4 H), 7.45–7.17 (m, 9 H), 7.15–7.10 (m, 1 H), 7.01 (tm, J = 7.6 Hz, 1 H), 6.92 (t, br, J 365 
= 7.2 Hz, 1 H), 1.52 (d, 2JH,P = 4.4 Hz, 3 H) ppm. 31P{1H} NMR (162 MHz): δ = +108.2 (d, 4JP,P = 366 
2.1 Hz), –38.2 (s) ppm. 367 
 368 
Compound 4: The procedure was the same as that used to obtain 3. From hydroxyphosphane C′ (242 369 
mg, 0.94 mmol), the title product was obtained as a white, pasty solid, yield 396 mg (95 %). 1H NMR 370 
(400 MHz): δ = 7.64–7.57 (m, 3 H), 7.37–7.33 (m, 6 H), 7.30–7.20 (m, 8 H), 7.11 (m, 1 H), 7.04 (td, J = 371 
7.6, 1.2 Hz, 1 H), 1.24 (d, 3JH,P = 12.4 Hz, 9 H) ppm. 31P{1H} NMR (162 MHz): δ = +108.6 (d, 4JP,P 372 
= 3.6 Hz), +0.8 (d, 4JP,P = 3.4 Hz) ppm. 373 
 374 
Compound 5: Hydroxyphosphane C (179 mg, 0.83 mmol) was dissolved in toluene (20 mL), and 375 
triethylamine (0.2 mL, 1.5 mmol) was added rapidly by syringe. To this mixture, a solution of the 376 
chlorodioxaphosphepine derived from (R)-(+)-1,1′-bi(2-naphthol)[37] (291 mg, 0.83 mmol) in toluene 377 
(10 mL) was added dropwise over 15 min, and the suspension was stirred for 1 h. The ammonium salts 378 
were removed by filtration, and the filtrate was brought to dryness to afford the title product as a white 379 
solid, yield 343 mg (78 %). 31P{1H} NMR (162 MHz): δ = +143.37 (d, 4JP,P = 20.1 Hz), –36.50 (d, 380 
4JP,P = 20.2 Hz) ppm. 381 
 382 
Compound 6: The procedure was the same as that used to obtain 5. From hydroxyphosphane C′ (245 383 
mg, 0.95 mmol), the title product was obtained as a white solid, yield 409 mg (75 %). 1H NMR (400 384 
MHz): δ = 7.31–7.09 (m, 10 H), 7.04 (dd, J = 8.0, 4.0 Hz, 1 H), 6.86–6.78 (m, 5 H), 6.74–6.68 (m, 2 H), 385 
6.64–6.55 (m, 3 H), 0.88 (d, 3JH,P = 12.4 Hz, 9 H) ppm. 31P{1H} NMR (162 MHz): δ = +144.31 (d, 386 
4JP,P = 41.5 Hz), +1.30 (d, 4JP,P = 41.3 Hz) ppm. 387 
 388 
Compound 7: The procedure was the same as that used to obtain 5 but with the 389 
chlorodioxaphosphepine derived from (S)-(–)-1,1′-bi(2-naphthol). From hydroxyphosphane C (378 mg, 390 
1.75 mmol), the title product was obtained as a white solid, yield 770 mg (83 %). 1H NMR (400 MHz): 391 
δ = 7.99 (d, J = 8.8 Hz, 1 H), 7.93 (t, J = 8.4 Hz, 1 H), 7.91 (t, J = 8.8 Hz, 1 H), 7.55 (d, J = 8.8 Hz, 1 H), 392 
7.52 (d, J = 8.8 Hz, 1 H), 7.47–7.41 (m, 4 H), 7.38 (d, J = 6.8 Hz, 2 H), 7.31–7.25 (m, 6 H), 7.22–7.08 393 
(m, 4 H), 1.57 (d, 2JH,P = 4.0 Hz, 3 H) ppm. 31P{1H} NMR (162 MHz): δ = +143.45 (d, 4JP,P = 16.7 394 
Hz), –37.38 (d, 4JP,P = 16.7 Hz) ppm. 395 
Compound 8: The procedure was the same as that used to obtain 7. From hydroxyphosphane C′ (379 396 
mg, 1.47 mmol), the title product was obtained as a white solid, yield 660 mg (78 %). 1H NMR (400 397 
MHz, C6D6): δ = 8.00 (d, J = 8.8 Hz, 1 H), 7.83 (t, J = 8.8 Hz, 2 H), 7.81–7.63 (m, 3 H), 7.66 (t, J = 8.8 398 
Hz, 2 H), 7.53 (d, J = 8.8 Hz, 1 H), 7.39 (dd, J = 8.4, 4.4 Hz, 1 H), 7.34–7.29 (m, 2 H), 7.27–7.18 (m, 5 399 
H), 7.15–7.02 (m, 3 H), 7.02 (t, J = 6.8 Hz, 1 H), 1.42 (d, 3JH,P = 12.4 Hz, 9 H) ppm. 31P{1H} NMR 400 
(162 MHz): δ = +142.33 (d, 4JP,P = 28.8 Hz), +0.80 (d, 4JP,P = 29.0 Hz) ppm. 401 
 402 
Compound 9: The procedure was the same as that used to obtain 7. From hydroxyphosphane C′′ (242 403 
mg, 0.87 mmol), the title product was obtained as a white solid, yield 480 mg (93 %). The 404 
characterisation data of this compound agreed with the values reported previously.[16] 1H NMR (400 405 
MHz): δ = 7.87 (d, J = 8.8 Hz, 1 H), 7.84 (d, J = 8.4 Hz, 1 H), 7.79 (d, J = 8.0 Hz, 1 H), 7.68 (d, J = 8.8 406 
Hz, 1 H), 7.38–7.23 (m, 16 H), 7.21–7.12 (m, 4 H), 6.99 (t, J = 7.2 Hz, 1 H), 6.70 (ddd, J = 7.6, 4.0 Hz, 407 
1.6 1 H) ppm. 31P{1H} NMR (162 MHz): δ = +143.21 (d, 4JP,P = 14.7 Hz), –16.00 (d, 4JP,P = 14.7 408 
Hz) ppm.  409 
 410 
Compound 10: Hydroxyphosphane C (134 mg, 0.62 mmol) was dissolved in toluene (20 mL), and 411 
triethylamine (0.2 mL, 1.5 mmol) and 4-dimethylaminopyridine (DMAP, 2 mg, 0.016 mmol) were 412 
added rapidly. To this mixture, a solution of the chlorodiazaphosphepine derived from (R)-N,N′-413 
dimethyl-1,1′-binaphthyldiamine[14d] (0.62 mmol) in toluene (10 mL) was added dropwise over 15 414 
min, and the suspension was stirred for 1 h. The ammonium salts were removed by filtration, and the 415 
filtrate was brought to dryness to afford the title product as a white solid, yield 311 mg (90 %). 1H NMR 416 
(400 MHz): δ = 7.93–7.84 (m, 4 H), 7.60 (d, J = 8.8 Hz, 1 H), 7.49 (d, J = 8.8 Hz, 1 H), 7.41–7.30 (m, 2 417 
H), 7.27–7.10 (m, 11 H), 6.98–6.95 (m, 2 H), 3.06 (d, 3JH,P = 13.6 Hz, 3 H), 2.89 (d, 3JH,P = 9.6 Hz, 3 418 
H), 1.35 (d, 2JH,P = 4.4 Hz, 3 H) ppm. 31P{1H} NMR (162 MHz): δ = +170.59 (d, 4JP,P = 7.0 Hz), –419 
37.86 (d, 4JP,P = 6.8 Hz) ppm.  420 
 421 
Compound 11: The procedure was the same as that used to obtain 10. From hydroxyphosphane C′ (206 422 
mg, 0.80 mmol), the title product was obtained as a white solid, yield 450 mg (94 %). 1H NMR (400 423 
MHz): δ = 8.07–7.82 (m, 5 H), 7.71–7.58 (m, 3 H), 7.49–7.32 (m, 5 H), 7.29–6.98 (m, 8 H), 3.09 (d, 424 
3JH,P = 12.0 Hz, 3 H), 3.03 (d, 3JH,P = 14.0 Hz, 3 H), 1.03 (d, 3JH,P = 12.4 Hz, 9 H) ppm. 31P{1H} 425 
NMR (162 MHz): δ = +172.16 (d, 4JP,P = 16.0 Hz), +0.23 (d, 4JP,P = 15.9 Hz) ppm. Compound 12: 426 
The procedure was the same as that used to obtain 10 but with the chlorodiazaphosphepine derived from 427 
(S)-N,N′-dimethyl-1,1′-binaphthyldiamine. From hydroxyphosphane C (162 mg, 0.75 mmol), the title 428 
product was obtained as a white solid, yield 371 mg (89 %). 1H NMR (400 MHz): δ = 8.00 (dd, J = 8.8, 429 
2.4 Hz, 1 H), 7.96–7.92 (m, 2 H), 7.88 (d, J = 3.2 Hz, 1 H), 7.86 (d, J = 2.8 Hz, 1 H), 7.81 (d, J = 8.8 Hz, 430 
1 H), 7.67 (d, J = 8.8 Hz, 1 H), 7.62 (d, J = 9.2 Hz, 1 H), 7.46–7.32 (m, 4 H), 7.28–7.10 (m, 6 H), 7.07–431 
6.95 (m, 3 H), 3.09 (d, 3JH,P = 9.6 Hz, 3 H), 3.05 (d, 3JH,P = 14.0 Hz, 3 H), 1.47 (d, 2JH,P = 4.0 Hz, 3 432 
H) ppm. 31P{1H} NMR (162 MHz): δ = +172.71 (d, 4JP,P = 11.0 Hz), –37.38 (d, 4JP,P = 11.0 Hz) 433 
ppm. 434 
 435 
Compound 13: The procedure was the same as that used to obtain 12. From hydroxyphosphane C′ (206 436 
mg, 0.80 mmol), the title product was obtained as a white solid, yield 380 mg (79 %). 1H NMR (400 437 
MHz): δ = 7.57 (dd, J = 8.8, 0.8 Hz, 1 H), 7.45–7.39 (m, 4 H), 7.26–7.21 (m, 4 H), 7.12 (dd, J = 8.4, 1.2 438 
Hz, 1 H), 7.08 (dd, J = 8.4, 1.2 Hz, 1 H), 6.93 (ddt, J = 8.0, 4.4, 0.8 Hz, 1 H), 6.90–6.61 (m, 8 H), 6.58 439 
(td, J = 7.2, 1.2 Hz, 1 H), 2.73 (d, 3JH,P = 9.2 Hz, 3 H), 2.62 (d, 3JH,P = 14.0 Hz, 3 H), 0.91 (d, 3JH,P = 440 
12.0 Hz, 3 H) ppm. 31P{1H} NMR (162 MHz): δ = +171.34 (d, 4JP,P = 8.9 Hz), –0.67 (d, 4JP,P = 8.9 441 
Hz) ppm. 442 
 443 
Compound 14: The procedure was the same as that used to obtain 12. From hydroxyphosphane C′′ (223 444 
mg, 0.80 mmol), the title product was obtained as a white solid, yield 408 mg (82 %). 1H NMR (400 445 
MHz): δ = 7.92 (d, J = 8.8 Hz, 1 H), 7.88 (d, J = 8.0 Hz, 1 H), 7.86 (d, J = 8.0 Hz, 1 H), 7.81 (d, J = 8.4 446 
Hz, 1 H), 7.61 (d, J = 8.8 Hz, 1 H), 7.41–7.10 (m, 19 H), 6.97 (t, J = 6.8 Hz, 1 H), 6.75 (dd, J = 6.8, 4.8 447 
Hz, 1 H), 2.92 (d, 3JH,P = 13.2 Hz, 3 H), 2.89 (d, 3JH,P = 8.8 Hz, 3 H) ppm. 31P{1H} NMR (162 448 
MHz): δ = +170.48 (d, 4JP,P = 10.2 Hz), –17.51 (d, 4JP,P = 10.5 Hz) ppm. 449 
 450 
Complex Pd1: Phosphane–phosphinite 1 (195 mg, 0.59 mmol), Pd dimer D (92 mg, 0.23 mmol) and 451 
NH4PF6 (191 mg, 1.17 mmol) were suspended in dichloromethane (20 mL), and the suspension was 452 
stirred vigorously for 2 h. Water (20 mL) was added, and the mixture was extracted with 453 
dichloromethane (3 × 10 mL). The combined organic phase was washed with water, dried with 454 
anhydrous Na2SO4 and filtered, and the solvent was removed under vacuum. The crude product was 455 
recrystallised in dichloromethane/hexane to yield the title product as a white solid, yield 210 mg (71 %). 456 
Diastereomeric ratio: 1:1.8. IR: ν˜ = 2970, 2929, 1591, 1468, 1436, 1267, 1207, 1028, 899, 891, 839 457 
[ν(PF6 –)], 774, 736, 558 cm–1. 1H NMR (400 MHz): δ = 7.61 (t, J = 7.6 Hz, 2 H), 7.51–7.30 (m, 11 H, 458 
Ar), 7.23–7.18 (m, 5 H, Ar), 4.50 (t, J = 4.0 Hz, 1 H, ma), 4.47 (t, J = 3.6 Hz, 1 H, mi), 4.35 (t, J = 4.4 459 
Hz, 1 H, ma), 4.31 (t, J = 4.4 Hz, 1 H, mi), 3.39 (d, J = 10.4 Hz, 1 H, ma), 3.34 (d, J = 10.0 Hz, 1 H, mi), 460 
2.99 (d, J = 10.0 Hz, 1 H, mi), 2.88 (d, J = 10.0 Hz, 1 H, ma), 2.46–2.23 (m, 4 H,ma + mi), 2.29 (d, 461 
2JH,P = 9.6 Hz, 3 H, ma), 2.24 (d, 2JH,P = 9.2 Hz, 3 H, mi), 1.89 (s, 3 H, ma), 1.84 (s, 3 H, mi), 1.22 462 
(dd, 3JH,P, 3JH,H = 16.4, 7.2 Hz, 3 H, ma), 1.15 (dd, 3JH,P, 3JH,H = 18.4, 11.2 Hz, 3 H, ma), 1.08 (dd, 463 
3JH,P, 2JH,H = 7.2, 1.6 Hz, 3 H, mi), 1.03 (dd, 3JH,P, 2JH,H = 7.6, 3.2 Hz, 3 H, mi), 0.98 (dd, 3JH,P, 464 
3JH,H = 19.6, 7.2 Hz, 3 H, ma), 0.91 (dd, 3JH,P, 3JH,H = 16.8, 7.2 Hz, 3 H, mi), 0.85 (dd, 3JH,P, 465 
2JH,H = 16.0, 6.8 Hz, 3 H, ma) ppm. 13C{1H} NMR (101 MHz): δ = 158.3–123.0 (C, CH, Ar), 73.7 466 
(dd, 2JC,P = 30.5, 3.1 Hz, CH2, ma), 73.3 (dd, 2JC,P = 31.4, 2.2 Hz, CH2, mi), 64.6 (dd, 2JC,P = 30.2, 467 
2.1 Hz, CH2, mi), 64.2 (d, 2JC,P = 30.2 Hz, CH2, ma), 32.5 (d, 1JC,P = 11.3 Hz, CH, mi), 32.3 (d, 468 
1JC,P = 10.3 Hz, CH, ma), 30.5 (d, 1JC,P = 24.1 Hz, CH, mi), 30.2 (d, 1JC,P = 25.3 Hz, CH, mi), 24.2 469 
(s, CH3, mi), 24.1 (s, CH3, Ma), 17.8–16.5 (m, 8 × CH3, ma + mi), 16.1 (d, 1JC,P = 28.3 Hz, CH3, mi), 470 
15.0 (d, 1JC,P = 29.1 Hz, CH3, ma) ppm. 31P{1H} NMR (162 MHz): δ = +190.81 (d, 2JP,P = 63.7 Hz, 471 
ma), +190.41 (d, 2JP,P = 63.8 Hz, mi), –6.49 (d, 2JP,P = 63.7 Hz, ma), –7.49 (d, 2JP,P = 63.7 Hz, mi) 472 
ppm. C23H33F6OP3Pd (638.82): calcd. C 43.24, H 5.21; found C 42.81, H 5.69. 473 
 474 
Complex Pd2: The procedure was the same as that used to prepare Pd1. From ligand 2 (180 mg, 0.48 475 
mmol) and Pd dimer D (76 mg, 0.19 mmol), the product was obtained as a white solid, yield 230 mg (89 476 
%). Diastereomeric ratio: 1:1. IR: ν˜ = 2966, 2873, 1591, 1466, 1434, 1265, 1201, 1097, 1074, 1028, 477 
899, 878, 839 [ν(PF6 –)], 773, 747, 699, 558, 518 cm–1. 1H NMR (400 MHz): δ = 7.76–7.42 (m, 2 H, 478 
Ar), 7.59–7.42 (m, 10 H, Ar), 7.22–6.99 (m, 6 H, Ar), 4.36 (d, J = 3.6 Hz, 2 H), 4.34 (m, 1 H), 3.64 (t, J 479 
= 4.4 Hz, 1 H), 3.42 (d, J = 10.0 Hz, 1 H), 2.90 (d, J = 10.0 Hz, 1 H), 2.87 (d, J = 10.0 Hz, 1 H), 2.61 (m, 480 
1 H), 2.48 (m, 2 H), 2.38 (d, J = 11.6 Hz, 1 H), 2.36 (m, 2 H), 1.86 (s, 3 H), 1.54 (s, 3 H), 1.48–1.26 (m, 481 
12 H), 1.42 (d, 3JH,P = 16.8 Hz, 9 H), 1.35 (d, 3JH,P = 16.4 Hz, 9 H), 1.19–1.07 (m, 12 H) ppm. 482 
13C{1H} NMR (101 MHz): δ = 159.2–115.0 (C, CH, Ar), 77.8 (dd, 2JC,P = 31.8, 3.1 Hz, CH2), 76.1 483 
(dd, 2JC,P = 31.1, 2.9 Hz, CH2), 64.2 (dd, 2JC,P = 28.3, 1.7 Hz, CH2), 62.9 (dd, 2JC,P = 28.5, 1.6 Hz, 484 
CH2), 35.6 (d, 1JC,P = 22.0 Hz, C), 34.8 (d, 1JC,P = 22.6 Hz, C), 32.5 (d, 1JC,P = 12.6 Hz, 2CH), 31.2 485 
(d, 1JC,P = 27.3 Hz, CH), 30.8 (d, 1JC,P = 27.1 Hz, CH), 28.4 (d, 2JC,P = 2.3 Hz, 3 × CH3), 28.3 (d, 486 
2JC,P = 2.5 Hz, 3 × CH3), 23.72 (s, CH3), 23.69 (s, CH3), 18.2 (d, 2JC,P = 5.6 Hz, CH3), 18.0 (d, 487 
2JC,P = 4.9 Hz, CH3), 17.8 (s, CH3), 17.5 (d, 2JC,P = 5.5 Hz, CH3), 17.4 (d, 2JC,P = 6.6 Hz, CH3), 488 
17.1 (s, CH3), 16.7 (d, 2JC,P = 2.7 Hz, CH3), 16.2 (s, CH3) ppm. 31P{1H} NMR (162 MHz): δ = 489 
+186.54 (d, 2JP,P = 59.6 Hz), +185.67 (d, 2JP,P = 59.8 Hz), +25.06 (d, 2JP,P = 59.6 Hz), +23.72 (d, 490 
2JP,P = 59.6 Hz) ppm. C26H39F6OP3Pd (680.90): calcd. C 45.86, H 5.77; found C 47.13, H 6.61. 491 
 492 
Pd3: The procedure was the same as that used to prepare Pd1. From ligand 3 (200 mg, 0.50 mmol) and 493 
Pd dimer D (78 mg, 0.20 mmol), the product was obtained as a white solid, yield 215 mg (76 %). 494 
Diastereomeric ratio: 1:1.3. IR: ν˜ = 3064, 3009, 2916, 1590, 1466, 1437, 1386, 1265, 1199, 1128, 1103, 495 
1079, 1027, 999, 894, 839 [ν(PF6 –)], 777, 741, 693, 587, 558, 518, 475 cm–1. 1H NMR (400 MHz): δ 496 
= 7.62–7.23 (m, Ar), 6.74 (m, Ar), 4.58 (t, J = 3.6 Hz, 1 H, mi), 4.55 (t, J = 4.0 Hz, 1 H, ma), 4.37 (t, J = 497 
4.0 Hz, 1 H, mi), 4.30 (t, J = 4.0 Hz, 1 H, ma), 3.48 (d, J = 10.0 Hz, 1 H, ma), 3.41 (d, J = 10.8 Hz, 1 H, 498 
mi), 3.21 (d, J = 10.0 Hz, 1 H, ma), 2.97 (d, J = 10.0 Hz, 1 H, mi), 2.35 (d, 2JH,P = 9.6 Hz, 3 H, ma), 499 
2.34 (d, 2JH,P = 9.6 Hz, 3 H, mi), 1.96 (s, 3 H, mi), 1.79 (s, 3 H, ma) ppm. 13C{1H} NMR (101 MHz): 500 
δ = 155.7–119.1 (C, CH, Ar), 72.4 (d, 2JC,P = 34.0 Hz, CH2, ma), 72.0 (d, 2JC,P = 23.8 Hz, CH2, mi), 501 
69.45 (d, 2JC,P = 26.3 Hz, CH2, mi), 69.37 (d, 2JC,P = 28.3 Hz, CH2, ma), 24.2 (s, CH3, mi), 24.1 (s, 502 
CH3, ma), 15.2 (d, 1JC,P = 27.1 Hz, CH3, mi), 14.3 (d, 1JC,P = 28.4 Hz, CH3, ma) ppm. 31P{1H} 503 
NMR (162 MHz): δ = +151.53 (d, 2JP,P = 68.5 Hz, mi), +150.56 (d, 2JP,P = 68.2 Hz, ma), –5.06 (d, 504 
2JP,P = 68.0 Hz, ma), –5.87 (d, 2JP,P = 68.8 Hz, mi) ppm. C29H29F6OP3Pd (706.86): calcd. C 49.28, 505 
H 4.14; found C 49.64, H 4.58. 506 
Complex Pd4: The procedure was the same as that used to prepare Pd1. From ligand 4 (150 mg, 0.34 507 
mmol) and Pd dimer D (53 mg, 0.13 mmol), the product was obtained as a white solid, yield 157 mg (81 508 
%). Diastereomeric ratio: 1:1. IR: ν˜ = 3061, 2960, 2865, 1590, 1567, 1466, 1436, 1398, 1369, 1310, 509 
1264, 1197, 1104, 1073, 1026, 999, 831 [ν(PF6 –)], 773, 746, 694, 588, 558, 519, 481 cm–1. 1H NMR 510 
(400 MHz): δ = 7.78–7.32 (m, 31 H, Ar), 7.17–7.07 (m, 4 H, Ar), 6.91–6.84 (m, 3 H, Ar), 4.44–4.40 (m, 511 
2 H), 4.14 (t, J = 4.0 Hz, 1 H), 3.91 (dd, J = 5.6, 4.0 Hz, 1 H), 3.48 (d, J = 12.4 Hz, 1 H), 3.45 (d, J = 512 
10.4 Hz, 1 H), 2.95 (d, J = 10.8 Hz, 1 H), 2.81 (d, J = 9.6 Hz, 1 H), 1.81 (s, 3 H), 1.75 (s, 3 H), 1.49 (d, 513 
3JH,P = 16.8 Hz, 9 H), 1.43 (d, 3JH,P = 16.8 Hz, 9 H) ppm. 13C{1H} NMR (101 MHz): δ = 156.6–514 
116.9 (C, CH, Ar), 74.6 (dd, 2JC,P = 33.5, 3.0 Hz, CH2), 70.8 (dd, 2JC,P = 28.0, 2.9 Hz, CH2), 68.4 515 
(dd, 2JC,P = 28.0, 2.5 Hz, CH2), 35.0 (d, 1JC,P = 21.7 Hz, C), 34.2 (d, 1JC,P = 22.0 Hz, C), 28.17 (d, 516 
2JC,P = 6.9 Hz, 3 × CH3), 28.11 (d, 2JC,P = 6.9 Hz, 3 × CH3), 23.96 (s, CH3), 23.86 (s, CH3) ppm. 517 
31P{1H} NMR (162 MHz): δ = +148.71 (d, 2JP.P = 65.8 Hz), +148.45 (d, 2JP.P = 65.9 Hz), +29.74 (d, 518 
2JP.P = 65.8 Hz), +28.39 (d, 2JP.P = 65.8 Hz) ppm. C32H35F6OP3Pd (748.94): calcd. C 51.32, H 4.71; 519 
found C 53.15, H 5.47. 520 
 521 
Complex Pd5: The procedure was the same as that used to prepare Pd1. From ligand 5 (300 mg, 0.57 522 
mmol) and Pd dimer D (86 mg, 0.22 mmol), the product was obtained as a white solid, yield 270 mg (73 523 
%). Diastereomeric ratio: 1:2.7. IR: ν˜ = 3068, 1619, 1591, 1509, 1464, 1437, 1321, 1264, 1223, 1184, 524 
1068, 959, 841 [ν(PF6 –)], 774, 750, 695, 608, 558, 500 cm–1. 1H NMR (400 MHz): δ = 8.17–8.13 (m, 525 
Ar), 8.09–7.98 (m, Ar), 7.79–7.75 (m, Ar), 7.62–7.30 (m, Ar), 7.24–7.15 (m, Ar), 7.07–6.98 (m, Ar), 526 
4.45 (d, J = 9.6 Hz, 1 H, mi), 4.25 (d, J = 8.8 Hz, 1 H, ma), 3.73 (d, J = 4.4 Hz, 2 H, ma + mi), 3.62 (d, J 527 
= 16.8 Hz, 1 H, ma), 3.12 (d, J = 8.8 Hz, 1 H, mi), 3.00 (dd, J = 10.4, 2.8 Hz, 1 H, ma), 2.63 (d, br, J = 528 
11.6 Hz, 1 H, mi), 2.39 (d, 2JH,P = 10.0 Hz, 3 H, ma), 2.38 (d, 2JH,P = 10.0 Hz, 3 H, mi), 1.91 (s, 3 H, 529 
mi), 1.66 (s, 3 H, ma) ppm. 13C{1H} NMR (101 MHz): δ = 153.5–119.2 (C, CH, Ar), 75.5 (dd, 2JC,P = 530 
46.0, 3.7 Hz, CH2, ma), 73.2 (dd, 2JC,P = 47.9, 3.8 Hz, CH2, mi), 69.8–69.4 (m, 2 × CH2, ma + mi), 531 
24.0 (s, CH3, ma), 23.8 (s, CH3, mi), 14.0 (d, 1JC,P = 28.9 Hz, CH3, mi), 13.2 (d, 1JC,P = 28.8 Hz, 532 
CH3, ma) ppm. 31P{1H} NMR (162 MHz): δ = +145.71 (d, 2JP,P = 102.5 Hz, mi), +145.64 (d, 2JP,P = 533 
102.9 Hz, ma), –4.21 (d, 2JP,P = 102.9 Hz, ma), –4.90 (d, 2JP,P = 102.7 Hz, mi) ppm. 534 
C37H31F6O3P3Pd (836.96): calcd. C 53.10, H 3.73; found C 52.78, H 4.46. 535 
 536 
Complex Pd6: The procedure was the same as that used to prepare Pd1. From ligand 6 (380 mg, 0.66 537 
mmol) and Pd dimer D (105 mg, 0.27 mmol), the product was obtained as a white solid, yield 331 mg 538 
(70 %). Diastereomeric ratio: 1:1.8. IR: ν˜ = 3068, 2957, 2869, 1619, 1590, 1509, 1464, 1434, 1400, 539 
1322, 1264, 1225, 1184, 1068, 958, 927, 842 [ν(PF6–)], 773, 696, 609, 558 cm–1. 1H NMR (400 MHz): 540 
δ = 8.25–8.02 (m, Ar), 7.89–7.87 (m, Ar), 7.78–6.80 (m, Ar), 4.29 (d, J = 8.8 Hz, 1 H, mi), 3.83 (d, J = 541 
17.2 Hz, 1 H, Ma), 3.68–3.59 (m, 3 H, 2 × ma + mi), 3.10 (d, J = 8.0 Hz, 1 H, ma), 2.65 (d, J = 8.8 Hz, 1 542 
H, mi), 2.47 (d, J = 16.4 Hz, 1 H, mi), 1.93 (s, 3 H, mi), 1.57 (d, 3JH,P = 17.2 Hz, 9 H, ma), 1.49 (d, 543 
3JH,P = 16.4 Hz, 9 H, mi), 1.48 (s, 3 H, ma) ppm. 13C{1H} NMR (101 MHz): δ = 154.7–115.7 (C, CH, 544 
Ar), 78.9 (dd, 2JC,P = 46.4, 2.3 Hz, CH2, ma), 75.9 (d, 2JC,P = 48.5 Hz, CH2, mi), 70.1 (dd, 2JC,P = 545 
27.4, 7.5 Hz, CH2, mi), 69.5 (dd, 2JC,P = 25.9, 7.1 Hz, CH2, ma), 36.0 (d, 1JC,P = 21.3 Hz, C, ma), 546 
35.4 (d, 1JC,P = 22.9 Hz, C, mi), 28.3 (d, 2JC,P = 6.5 Hz, 3 × CH3, mi), 28.2 (d, 2JC,P = 6.6 Hz, 3 × 547 
CH3, ma), 23.7 (s, CH3, ma), 23.6 (s, CH3, mi) ppm. 31P{1H} NMR (162 MHz): δ = +144.42 (d, 2JP,P 548 
= 97.8 Hz, ma), +143.67 (d, 2JP,P = 98.7 Hz, mi), +29.52 (d, 2JP,P = 98.8 Hz, mi), +28.76 (d, 2JP,P = 549 
97.2 Hz, ma) ppm. C40H37F6O3P3Pd (879.04): calcd. C 54.65, H 4.24; found C 54.23, H 5.06. 550 
 551 
Complex Pd7: The procedure was the same as that used to prepare Pd1. From ligand 7 (400 mg, 0.75 552 
mmol) and Pd dimer D (123 mg, 0.31 mmol), the product was obtained as a white solid, yield 398 mg 553 
(77 %). Diastereomeric ratio: 1:1. IR: ν˜ = 3066, 2957, 2924, 1619, 1591, 1509, 1464, 1437, 1322, 1264, 554 
1224, 1185, 1128, 1068, 958, 919, 832 [ν(PF6–)], 774, 741, 695, 608, 558, 500 cm–1. 1H NMR (400 555 
MHz): δ = 8.24–8.02 (m, 4 H, Ar), 7.73–7.18 (m, 17 H, Ar), 4.79 (d, J = 7.6 Hz, 1 H), 4.53 (d, J = 8.0 556 
Hz, 1 H), 3.79–3.64 (m, 3 H), 3.32 (d, J = 15.6 Hz, 1 H), 3.07 (d, J = 9.6 Hz, 1 H), 2.69 (d, J = 7.2 Hz, 557 
1H), 2.43 (d, 2JH,P = 9.6 Hz, 3 H), 2.35 (d, 2JH,P = 9.6 Hz, 3 H), 1.97 (s, 3 H), 1.68 (s, 3 H) ppm. 558 
31P{1H} NMR (162 MHz): δ = +146.20 (d, 2JP,P = 103.2 Hz), +145.87 (d, 2JP,P = 102.7 Hz), –3.99 559 
(d, 2JP,P = 103.2 Hz), –5.42 (d, 2JP,P = 102.9 Hz) ppm. HRMS: calcd. For C37H31O3P2Pd [M – 560 
PF6]+ 691.0777; found 691.0793. 561 
 562 
Complex Pd8: The procedure was the same as that used to prepare Pd1. From ligand 8 (285 mg, 0.50 563 
mmol) and Pd dimer D (72 mg, 0.18 mmol), the product was obtained as a white solid, yield 207 mg (65 564 
%). Diastereomeric ratio: 1:2.3. IR: ν˜ = 3065, 2961, 2869, 1619, 1590, 1509, 1464, 1435, 1400, 1368, 565 
1322, 1263, 1223, 1184, 1068, 958, 836 [ν(PF6–)], 774, 750, 696, 603, 558, 515 cm–1. 1H NMR (400 566 
MHz): δ = 8.26–8.13 (m, Ar), 8.13–7.87 (m, Ar), 7.78–7.71 (m, Ar), 7.61–7.29 (m, Ar), 7.09–7.01 (m, 567 
Ar), 4.43 (d, J = 8.8 Hz, 1 H, ma), 4.21 (dd, J = 9.2, 2.4 Hz, 1 H, mi), 3.67 (s, br, 1 H, Ma), 3.47 (s, br, 568 
1H, mi), 3.36 (d, J = 16.4 Hz, 1 H, mi), 3.29 (d, J = 17.2 Hz, 1 H, ma), 3.09 (d, J = 10.0 Hz, 1 H, ma), 569 
2.57 (dd, J = 10.0, 3.6 Hz, 1 H, mi), 1.83 (s, 3 H, mi), 1.63 (s, 3 H, Ma), 1.54 (d, 3JH,P = 17.2 Hz, 9 H, 570 
mi), 1.49 (d, 3JH,P = 16.8 Hz, 9 H, ma) ppm. 13C{1H} NMR (101 MHz): δ = 153.8–118.2 (C, CH, Ar), 571 
75.4 (d, 2JC,P = 50.1 Hz, 2 × CH2, ma + mi), 70.7 (d, 2JC,P = 20.9 Hz, CH2, ma), 68.6 (d, 2JC,P = 19.9 572 
Hz, CH2, mi), 34.5 (d, 1JC,P = 20.5 Hz, C, mi), 34.2 (d, 1JC,P = 21.0 Hz, C, ma), 28.0 (d, 2JC,P = 6.9 573 
Hz, 3 × CH3, ma), 27.8 (d, 2JC,P = 6.5 Hz, 3 × CH3, mi), 23.82 (s, CH3, mi), 23.77 (s, CH3, ma) ppm. 574 
31P{1H} NMR (162 MHz): δ = +146.99 (d, 2JP,P = 95.9 Hz, ma), +146.75 (d, 2JP,P = 96.7 Hz, mi), 575 
+32.10 (d, 2JP,P = 96.6 Hz, mi), +32.01 (d, 2JP,P = 96.1 Hz, ma) ppm. C40H37F6O3P3Pd (879.04): 576 
calcd. C 54.65, H 4.24; found C 54.53, H 4.71. 577 
 578 
 579 
 580 
Complex Pd9: The procedure was the same as that used to prepare Pd1. From ligand 9 (320 mg, 0.54 581 
mmol) and Pd dimer D (81 mg, 0.21 mmol), the product was obtained as a white solid, yield 303 mg (80 582 
%). Diastereomeric ratio: 1:1.7. IR: ν˜ = 3061, 1619, 1590, 1509, 1463, 1437, 1323, 1265, 1224, 1184, 583 
1068, 958, 921, 841 [ν(PF6–)], 774, 749, 695, 609, 558, 517 cm–1. 1H NMR (400 MHz): δ = 8.24–8.19 584 
(m, Ar), 8.14–7.91 (m, Ar), 7.72–7.49 (m, Ar), 7.43–7.24 (m, Ar), 7.21–7.10 (m, Ar), 6.93–6.86 (m, 585 
Ar), 4.28 (d, J = 8.8 Hz, 1 H, mi), 4.10 (d, J = 8.8 Hz, 1 H, ma), 3.80 (d, J = 16.4 Hz, 1 H, ma), 3.74 (s, 586 
br, ma), 3.67 (s, br, mi), 3.33 (d, J = 16.4 Hz, 1 H, mi), 3.17 (dd, J = 10.4, 2.0 Hz, 1 H, ma), 2.78 (dd, J = 587 
10.0, 2.0 Hz, 1 H, mi), 1.96 (s, 3 H, mi), 1.70 (s, 3 H, ma) ppm. 13C{1H} NMR (101 MHz): δ = 153.5–588 
117.9 (C, CH, Ar), 75.2 (d, 2JC,P = 47.9 Hz, CH2, mi), 70.4 (dd, 2JC,P = 28.0, 6.5 Hz, CH2, ma), 70.0 589 
(dd, 2JC,P = 28.6, 7.5 Hz, CH2, mi), 24.06 (s, CH3, ma), 23.95 (s, CH3, mi) ppm. 31P{1H} NMR (162 590 
MHz): δ = +145.93 (d, 2JP,P = 100.9 Hz, ma), +145.66 (d, 2JP,P = 101.3 Hz, mi), +12.31 (d, 2JP,P = 591 
101.4 Hz, mi), +11.48 (d, 2JP,P = 100.9 Hz, ma) ppm. C42H33F6O3P3Pd (899.03): calcd. C 56.11, H 592 
3.70; found C 55.47, H 3.5. 593 
 594 
Complex Pd10: The procedure was the same as that used to prepare Pd1. From ligand 10 (320 mg, 0.57 595 
mmol) and Pd dimer D (94 mg, 0.24 mmol), the product was obtained as a white solid, yield 315 mg (76 596 
%). Diastereomeric ratio: 1:2.4. IR: ν˜ = 3195, 3063, 2957, 1619, 1591, 1507, 1466, 1437, 1329, 1263, 597 
1198, 1131, 1090, 1026, 944, 901, 843 [ν(PF6–)], 751, 697, 633, 606, 558, 499 cm–1. 1H NMR (400 598 
MHz): δ = 8.16–8.07 (m, Ar), 8.02–7.91 (m, Ar), 7.84–7.82 (m, Ar), 7.71–7.38 (m, Ar), 7.32–7.13 (m, 599 
Ar), 7.10–7.05 (m, Ar), 6.88–6.79 (m, Ar), 4.08 (d, J = 6.4 Hz, 1 H, mi), 3.78 (d, J = 4.8 Hz, 1 H, ma), 600 
3.73 (m, 1 H, mi), 3.59 (d, J = 13.6 Hz, 1 H, ma), 3.38 (s, br, 1 H, ma), 3.31 (d, 3JH,P = 10.4 Hz, 3 H, 601 
ma), 3.14 (d, 3JH,P = 10.8 Hz, 3 H, mi), 3.05 (d, J = 10.4 Hz, 1 H, ma), 2.89 (d, 3JH,P = 14.8 Hz, 3 H, 602 
mi), 2.84 (s, br, 1 H, mi), 2.73 (d, 3JH,P = 14.8 Hz, 3 H, ma), 2.49 (d, J = 9.6 Hz, 1 H, mi), 2.25 (d, 603 
2JH,P = 9.2 Hz, 3 H, ma), 2.14 (d, 2JH,P = 9.2 Hz, 3 H, mi), 1.95 (s, 3 H, mi), 1.57 (s, 3 H, ma) ppm. 604 
13C{1H} NMR (101 MHz): δ = 155.1–120.4 (C, CH, Ar), 73.8 (d, 2JC,P = 43.6 Hz, CH2, mi), 65.16 605 
(dd, 2JC,P = 30.0, 5.8 Hz, CH2, ma), 65.11 (d, 2JC,P = 31.1 Hz, CH2, mi), 39.58 (d, 2JC,P = 31.9 Hz, 606 
CH3, ma), 39.54 (d, 2JC,P = 30.2 Hz, CH3, mi), 35.92 (d, 2JC,P = 12.2 Hz, CH3, ma), 35.84 (d, 2JC,P 607 
= 12.6 Hz, CH3, mi), 24.0 (s, CH3, ma), 23.9 (s, CH3, mi), 13.4 (d, 1JC,P = 29.2 Hz, CH3, mi), 12.5 (d, 608 
1JC,P = 28.6 Hz, CH3, ma) ppm. 31P{1H} NMR (162 MHz): δ = +156.57 (d, 2JP,P = 85.2 Hz, mi), 609 
+155.95 (d, 2JP,P = 87.2 Hz, ma), –4.25 (d, 2JP,P = 87.2 Hz, ma), –5.92 (d, 2JP,P = 85.2 Hz, mi) ppm. 610 
HRMS: calcd. for C39H37N2OP2Pd [M – PF6]+ 717.1410; found 717.1435. 611 
 612 
Complex Pd11: The procedure was the same as that used to prepare Pd1. From ligand 11 (450 mg, 0.75 613 
mmol) and Pd dimer D (118 mg, 0.30 mmol), the product was obtained as a white solid, yield 375 mg 614 
(69 %). Diastereomeric ratio: 1:2.1. IR: ν˜ = 3063, 2959, 2870, 1619, 1591, 1507, 1466, 1434, 1329, 615 
1262, 1198, 1091, 944, 876, 842 [ν(PF6–)], 771, 748, 697, 633, 606, 558, 517 cm–1. 1H NMR (400 616 
MHz): δ = 8.19–7.86 (m, Ar), 7.71–7.40 (m, Ar), 7.39–7.11 (m, Ar), 7.06–6.95 (m, Ar), 4.34 (d, J = 6.0 617 
Hz, 1 H, mi), 3.91 (s, br, 1 H, mi), 3.68 (d, J = 15.2 Hz, 1 H, ma), 3.64 (dd, J = 9.2, 3.2 Hz, 1 H, ma), 618 
3.34 (s, br, 1 H, ma), 3.28 (d, 3JH,P = 10.0 Hz, 3 H, ma), 3.17 (d, J = 10.0 Hz, 1 H, ma), 3.11 (d, 3JH,P 619 
= 10.4 Hz, 3 H, mi), 3.01 (d, 3JH,P = 15.2 Hz, 3 H, mi), 2.82 (d, 3JH,P = 14.4 Hz, 3 H, ma), 2.45 (d, J = 620 
9.2 Hz, 1 H, mi), 2.36 (d, J = 14.0 Hz, 1 H, mi), 1.97 (s, 3 H, mi), 1.52 (d, 3JH,P = 16.8 Hz, 9 H, ma), 621 
1.43 (d, 3JH,P = 16.8 Hz, 9 H, mi), 1.33 (s, 3 H, ma) ppm. 13C{1H} NMR (101 MHz): δ = 156.3–121.8 622 
(C, CH, Ar), 74.9 (d, CH2, mi), 65.4 (dd, 2JC,P = 27.3, 5.2 Hz, CH2, ma), 64.6 (d, 2JC,P = 27.8 Hz, 623 
CH2, mi), 39.85 (d, 2JC,P = 30.1 Hz, CH3, mi), 39.75 (d, 2JC,P = 31.9 Hz, CH3, ma), 36.49 (d, 2JC,P = 624 
11.3 Hz, CH3, mi), 36.28 (d, 2JC,P = 11.2 Hz, CH3, ma), 35.9 (d, 1JC,P = 21.1 Hz, C, ma), 35.2 (d, 625 
1JC,P = 22.4 Hz, C, mi), 28.6 (d, 2JC,P = 7.0 Hz, 3 × CH3, mi), 28.2 (d, 2JC,P = 6.6 Hz, 3 × CH3, ma), 626 
23.73 (s, CH3, mi), 23.70 (s, CH3, ma) ppm. 31P{1H} NMR (162 MHz): δ = +153.98 (d, 2JP,P = 81.0 627 
Hz, ma), +153.09 (d, 2JP,P = 80.7 Hz, mi), +27.73 (d, 2JP,P = 80.7 Hz, mi), +26.96 (d, 2JP,P = 81.0 Hz, 628 
ma) ppm. C42H43F6N2OP3Pd (905.12): calcd. C 55.73, H 4.79, N 3.09; found C 55.96, H 5.19, N 3.02. 629 
 630 
Complex Pd12: The procedure was the same as that used to prepare Pd1. From ligand 12 (300 mg, 0.54 631 
mmol) and Pd dimer D (84 mg, 0.21 mmol), the product was obtained as a white solid, yield 210 mg (58 632 
%). Diastereomeric ratio: 1:1. IR: ν˜ = 3064, 2962, 1619, 1592, 1507, 1467, 1438, 1329, 1275, 1200, 633 
1090, 944, 843 [ν(PF6–)], 740, 697, 633, 605, 558, 509 cm–1. 1H NMR (400 MHz): δ = 8.18–7.04 (m, 634 
4 H, Ar), 8.03–7.88 (m, 4 H, Ar), 7.83–7.67 (m, 5 H, Ar), 7.62–7.33 (m, 16 H, Ar), 7.31–7.05 (m, 13 H, 635 
Ar), 4.76 (d, J = 6.0 Hz, 1 H), 4.50 (d, J = 4.0 Hz, 1 H), 3.67 (d, J = 14.0 Hz, 1 H), 3.53 (t, J = 4.4 Hz, 1 636 
H), 3.38 (s, 1 H), 3.34 (d, J = 14.0 Hz, 1 H), 3.15 (d, J = 10.4 Hz, 1 H), 2.86 (d, 3JH,P = 14.8 Hz, 3 H), 637 
2.68 (d, 3JH,P = 14.4 Hz, 3 H), 2.54 (d, 3JH,P = 10.4 Hz, 3 H), 2.51 (d, J = 8.0 Hz, 1 H), 2.39 (d, 3JH,P 638 
= 10.4 Hz, 3 H), 2.36 (d, 2JH,P = 10.0 Hz, 3 H), 2.30 (d, 2JH,P = 9.6 Hz, 3 H), 2.07 (s, 3 H), 1.66 (s, 3 639 
H) ppm. 13C{1H} NMR (101 MHz): δ = 154.6–121.3 (C, CH, Ar), 71.3 (d, 2JC,P = 39.9 Hz, CH2), 640 
71.2 (d, 2JC,P = 40.3 Hz, CH2), 67.2 (d, 2JC,P = 35.0 Hz, CH2), 65.0 (d, 2JC,P = 34.6 Hz, CH2), 39.6 641 
(d, 2JC,P = 31.8 Hz, CH3), 39.4 (d, 2JC,P = 29.7 Hz, CH3), 35.03 (d, 2JC,P = 11.8 Hz, CH3), 35.00 (d, 642 
2JC,P = 12.1 Hz, CH3), 24.2 (s, CH3), 24.1 (s, CH3), 16.3 (d, 1JC,P = 28.8 Hz, CH3), 14.8 (d, 1JC,P = 643 
26.3 Hz, CH3) ppm. 31P{1H} NMR (162 MHz): δ = +158.83 (d, 2JP,P = 84.6 Hz), +158.66 (d, 2JP,P = 644 
85.2 Hz), –3.16 (d, 2JP,P = 84.7 Hz), –4.95 (d, 2JP,P = 85.1 Hz) ppm. HRMS: calcd. for 645 
C39H37N2OP2Pd [M – PF6]+ 717.1410; found 717.1437. 646 
 647 
Complex Pd13: The procedure was the same as that used to prepare Pd1. From ligand 13 (150 mg, 0.25 648 
mmol) and Pd dimer D (40 mg, 0.10 mmol), the product was obtained as a white solid, yield 122 mg (67 649 
%). Diastereomeric ratio: 1:2. IR: ν˜ = 3064, 2963, 1619, 1591, 1507, 1467, 1435, 1329, 1262, 1199, 650 
1090, 943, 842 [ν(PF6–)], 774, 750, 697, 601, 557, 518 cm–1. 1H NMR (400 MHz): δ = 8.15–8.05 (m, 651 
Ar), 7.99–7.90 (m, Ar), 7.86–7.81 (m, Ar), 7.73–7.66 (m, Ar), 7.58–7.41 (m, Ar), 7.31–7.07 (m, Ar), 652 
4.57–4.53 (m, 2 H, ma +mi), 3.68 (d, J = 14.0 Hz, 1 H, ma), 3.33 (d, J = 14.0 Hz, 1 H, mi), 3.20–3.12 653 
(m, 3 H, 2 × ma + mi), 2.84 (d, 3JH,P = 14.8 Hz, 3 H, mi), 2.65 (d, 3JH,P = 14.4 Hz, 3 H, ma), 2.38 (d, 654 
3JH,P = 10.0 Hz, 3 H, ma), 2.22 (d, 3JH,P = 9.6 Hz, 3 H, mi), 2.03 (s, 3 H, mi), 1.61 (s, 3 H, ma), 1.50 655 
(d, 3JH,P = 16.4 Hz, 9 H, mi), 1.47 (d, 3JH,P = 16.4 Hz, 9 H, ma) ppm. 13C{1H} NMR (101 MHz): δ = 656 
155.2–120.1 (C, CH, Ar), 73.4 (d, 2JC,P = 44.0 Hz, CH2, ma), 67.5 (d, 2JC,P = 22.6 Hz, CH2, ma), 657 
39.2 (d, 2JC,P = 30.9 Hz, CH3, ma), 35.1 (d, 2JC,P = 10.8 Hz, CH3, ma), 32.9 (d, 1JC,P = 19.6 Hz, C, 658 
mi), 32.3 (d, 1JC,P = 19.4 Hz, C, ma), 27.4 (d, 2JC,P = 6.3 Hz, 3 × CH3, mi), 27.1 (d, 2JC,P = 6.9 Hz, 3 659 
× CH3, ma), 23.9 (s, CH3, ma), 23.8 (s, CH3, mi) ppm. 31P{1H} NMR (162 MHz): δ = +157.80 (d, 660 
2JP,P = 77.6 Hz, ma), +154.36 (d, 2JP,P = 78.2 Hz, mi), +35.38 (d, 2JP,P = 78.2 Hz, mi), +35.34 (d, 661 
2JP,P = 77.4 Hz, ma) ppm. C42H43F6N2OP3Pd (905.12): calcd. C 55.73, H 4.79, N 3.09; found C 662 
53.22, H 5.01, N 3.08. 663 
 664 
Complex Pd14: The procedure was the same as that used to prepare Pd1. From ligand 14 (320 mg, 0.52 665 
mmol) and Pd dimer D (81 mg, 0.21 mmol), the product was obtained as a white solid, yield 303 mg (78 666 
%). Diastereomeric ratio: 1:1. IR: ν˜ = 3063, 1618, 1591, 1507, 1465, 1437, 1329, 1263, 1200, 1090, 667 
944, 842 [ν(PF6–)], 749, 697, 607, 558, 519 cm–1. 1H NMR (400 MHz): δ = 8.14 (d, J = 7.2 Hz, 1 H), 668 
8.12 (d, J = 6.4 Hz, 2 H), 8.09 (d, J = 6.4 Hz, 1 H), 8.00 (d, J = 3.6 Hz, 1 H), 7.98 (d, J = 4.0 Hz, 1 H), 669 
7.96 (d, J = 8.4 Hz, 1 H), 7.91 (d, J = 8.4 Hz, 1 H), 7.85 (d, J = 8.8 Hz, 1 H), 7.70 (q, J = 8.0 Hz, 2 H), 670 
7.73–7.36 (m, 20 H, Ar), 7.32–7.16 (m, 17 H, Ar), 7.12–7.08 (m, 2 H, Ar), 6.79 (m, 2 H, Ar), 4.31 (d, J 671 
= 6.0 Hz, 1 H), 3.99 (dd, J = 7.2, 2.4 Hz, 1 H), 3.86 (d, J = 13.6 Hz, 1 H), 3.61 (t, J = 4.4 Hz, 1 H), 3.41 672 
(s, br, 1 H), 3.32 (d, J = 13.6 Hz, 1 H), 3.22 (d, J = 10.4 Hz, 1 H), 2.99 (d, 3JH,P = 15.2 Hz, 3 H), 2.80 673 
(d, 3JH,P = 14.8 Hz, 3 H), 2.74 (dd, J = 10.4, 2.0 Hz, 1 H), 2.56 (d, 3JH,P = 10.8 Hz, 3 H), 2.35 (d, 674 
3JH,P = 10.4 Hz, 3 H), 2.02 (s, 3 H), 1.70 (s, 3 H) ppm. 13C{1H} NMR (101 MHz): δ = 147.8–121.0 675 
(C, CH, Ar), 39.8 (d, 2JC,P = 28.0 Hz, CH3), 39.6 (d, 2JC,P = 31.2 Hz, CH3), 34.7 (d, 2JC,P = 17.0 Hz, 676 
CH3), 34.6 (d, 2JC,P = 17.0 Hz, CH3), 24.2 (s, CH3), 24.0 (s, CH3) ppm. 31P{1H} NMR (162 MHz): δ 677 
= +158.84 (d, 2JP,P = 84.7 Hz), +158.62 (d, 2JP,P = 83.3 Hz), +13.21 (d, 2JP,P = 83.3 Hz), 12.65 (d, 678 
2JP,P = 84.7 Hz) ppm. C44H39F6N2OP3Pd (925.11): calcd. C 57.12, H 4.25, N 3.03; found C 56.14, H 679 
4.56, N 3.03. 680 
 681 
Complex Pd6′: The procedure was the same as that used to prepare Pd1. From ligand 6 (300 mg, 0.52 682 
mmol) and Pd dimer D′ (135 mg, 0.2 mmol), the product was obtained as a white solid, yield 253 mg 683 
(62 %). Diastereomeric ratio: 1:3.5. IR: ν˜ = 3057, 2957, 1596, 1470, 1430, 1183, 1070, 957, 848 684 
[ν(PF6–)], 745, 561 cm–1. 1H NMR (400 MHz): δ = 8.47–6.18 (m, 40 H, Ar), 6.06–5.90 (m, 4 H, 2 × 685 
ma + 2 × mi), 5.24–5.19 (m, 2 H, ma + mi), 1.43 (d, 3JH,P = 17.2 Hz, 9 H, ma), 1.08 (d, 3JH,P = 16.8 686 
Hz, 9 H, mi) ppm. 13C{1H} NMR (101 MHz): δ = 154.8–118.5 (C, CH, Ar), 112.73 (d, 2JC,P = 7.9 Hz, 687 
CH), 112.60 (d, 2JC,P = 8.2 Hz, CH), 100.22 (d, 2JC,P = 4.5 Hz, CH), 99.86 (d, 2JC,P = 4.8 Hz, CH), 688 
86.36 (d, 2JC,P = 10.5 Hz, CH), 86.13 (d, 2JC,P = 10.7 Hz, CH), 36.79 (d, 1JC,P = 19.7 Hz, C, mi), 689 
36.72 (d, 1JC,P = 18.6 Hz, C, ma), 27.9 (d, 2JC,P = 6.2 Hz, 6 × CH3, ma + mi) ppm. 31P{1H} NMR 690 
(162 MHz): δ = +139.57 (d, 2JP,P = 138.0 Hz, ma), +137.27 (d, 2JP,P = 144.5 Hz, mi), +29.87 (d, 2JP,P 691 
= 138.0 Hz, ma), +26.75 (d, 2JP,P = 144.3 Hz, mi) ppm. HRMS: calcd. for C51H43O3P2Pd [M – PF6]+ 692 
871.1716; found 871.1733. 693 
 694 
Allylic Alkylations with Dimethyl Malonate: Under a nitrogen atmosphere, the appropriate Pd 695 
complex (0.01 mmol), the precursor I, II or III (1 mmol), dimethyl malonate (3 mmol), BSA (3 mmol) 696 
and KOAc (1 mg) were dissolved in dichloromethane (5 mL) in this precise order. The flask was 697 
covered with aluminium foil, and the mixture was stirred for the allotted time. To quench the reaction, 698 
diethyl ether (20 mL) and aqueous 10 % ammonium chloride solution (20 mL) were added. After 699 
extraction, the organic phase was dried with anhydrous sodium sulfate and filtered, and the solvent was 700 
removed in vacuo. The crude product was analysed by 1H NMR spectroscopy to estimate the 701 
conversion. The crude product was dissolved in ethyl acetate, and the solution was passed through a 702 
column of silica to remove the metallic impurities. The eluent was removed in vacuo, and the residue 703 
was analysed by NMR spectroscopy and HPLC (alkylations of I) or GC (alkylations of II and III). 704 
 705 
Allylic Amination of I with Benzylamine: Under a nitrogen atmosphere, the Pd complex (0.01 mmol), 706 
I (1 mmol) and benzylamine (3 mmol) were dissolved in dichloromethane (5 mL) in this precise order. 707 
The flask was covered with aluminium foil, and the mixture was stirred for 72 h. To quench the reaction, 708 
diethyl ether (20 mL) and aqueous 10 % ammonium chloride solution (20 mL) were added. After 709 
extraction, the organic phase was dried with anhydrous sodium sulfate and filtered, and the solvent was 710 
removed in vacuo. The crude product was analysed by 1H NMR spectroscopy to estimate the 711 
conversion. The crude product was dissolved in ethyl acetate, and the solution was passed through a 712 
column of silica to remove the metallic impurities. The eluent was removed in vacuo, and the residue 713 
was analysed by NMR spectroscopy and HPLC. 714 
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Legends to figures 830 
 831 
Scheme 1. Retrosynthetic route to the PP′ ligands. 832 
 833 
Scheme 2. Preparation of PP′ ligands 1–14. 834 
 835 
Figure 1. Prepared PP′ ligands 1–14. 836 
 837 
Scheme 3. Preparation of Pd complexes Pd1–Pd14. 838 
 839 
Figure 2. ORTEP representations (thermal ellipsoids drawn at 50 % of probability level, H atoms and 840 
PF6 – anions removed for clarity) of Pd1 (left) and Pd2 (right). Distances [Å] and angles [°] for Pd1: 841 
Pd–P(1) 2.2904(6), Pd–P(2) 2.2510(6), Pd–C(20) 2.206(3), Pd–C(21) 2.212(2), Pd–C(22) 2.159(2), 842 
C(20)–C(21) 1.402(4), C(21)–C(22) 1.419(4), P(1)–Pd–Pd(2) 92.11(2), P(2)–Pd–C(22) 97.92(7), C(22)–843 
Pd–C(20) 67.19(10), C(20)–Pd–P(1) 102.67(8); for Pd2: Pd–P(1) 2.232(2), Pd–P(2) 2.286(3), Pd–C(24) 844 
2.087(10), Pd–C(25) 2.299(12), Pd–C(26) 2.552(12), C(24)–C(25) 1.366(17), C(24)–C(26) 1.447(17), 845 
C(24)–C(23) 1.365(15), P(1)–Pd–Pd(2) 94.67(9), P(1)–Pd–C(25) 125.6(3), C(25)–Pd–C(26) 61.1(4), 846 
C(26)–Pd–P(2) 76.4(3). 847 
 848 
 849 
Figure 3. ORTEP representation (thermal ellipsoids drawn at 50 % of probability level, H atoms, water 850 
molecules and the PF6 – anion removed for clarity) of Pd13. Distances [Å] and angles [°]: Pd–P(1) 851 
2.2568(13), Pd–P(2) 2.3192(14), Pd–C(39) 2.177(5), Pd–C(40) 2.189(6), Pd–C(41) 2.158(6), C(39)–852 
C(40) 1.428(9), C(40)–C(41) 1.376(8), C(40)–C(42) 1.517(9), P(1)–N(1) 1.683(4), P(1)–N(2) 1.656(5), 853 
P(1)–Pd–P(2) 91.60(5), P(2)–Pd–C(39) 104.10(18), C(39)–Pd–C(41) 66.6(2), C(41)–Pd–P(1) 97.63(16), 854 
ΣN(1) 346.7, ΣN(2) 357.1. 855 
 856 
Scheme 4. Allylic substitution reactions of I catalysed by Pd1–Pd14 complexes. 857 
 858 
Scheme 5. Preparation of complex Pd6′. 859 
 860 
Scheme 6 Allylic alkylation of II and III catalysed by Pd complexes. 861 
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